Charles Schwab Investment Management Inc. Purchases 48,402 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Charles Schwab Investment Management Inc. boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 33.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 191,165 shares of the company’s stock after acquiring an additional 48,402 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.28% of EyePoint Pharmaceuticals worth $1,424,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EYPT. Geode Capital Management LLC increased its stake in shares of EyePoint Pharmaceuticals by 16.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock worth $9,583,000 after purchasing an additional 166,699 shares during the last quarter. Barclays PLC increased its position in EyePoint Pharmaceuticals by 410.4% during the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after buying an additional 197,033 shares during the last quarter. JPMorgan Chase & Co. increased its position in EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock worth $2,970,000 after buying an additional 342,516 shares during the last quarter. Franklin Resources Inc. raised its holdings in EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock valued at $32,056,000 after buying an additional 362,399 shares in the last quarter. Finally, Patient Square Capital LP acquired a new stake in shares of EyePoint Pharmaceuticals in the third quarter worth about $10,882,000. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $5.83 on Friday. The stock has a market cap of $400.69 million, a P/E ratio of -2.92 and a beta of 1.41. The company has a fifty day moving average price of $6.79 and a 200 day moving average price of $8.23. EyePoint Pharmaceuticals, Inc. has a one year low of $5.54 and a one year high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. As a group, equities research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analysts Forecast Growth

EYPT has been the topic of a number of recent analyst reports. Citigroup assumed coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.